
TSVT
Healthcare · Biotechnology · $266.1M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2025
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 1, 2025 | Before the open | -0.81 | 0.01 | +101.2% |
| Mar 3, 2025 | Before the open | -0.10 | -0.31 | -206.1% |
| Nov 12, 2024 | Before the open | -0.24 | -0.19 | +20.8% |
| Aug 7, 2024 | Before the open | -0.65 | 0.45 | +169.2% |
| May 8, 2024 | Before the open | -0.81 | -1.01 | -24.7% |
| Mar 5, 2024 | Before the open | -0.99 | -1.11 | -12.1% |
| Nov 14, 2023 | Before the open | -1.03 | -1.00 | +2.9% |
| Aug 14, 2023 | Before the open | -1.15 | -0.83 | +27.8% |
| May 3, 2023 | After the close | -1.22 | -1.08 | +11.5% |
| Mar 16, 2023 | After the close | -1.61 | -0.60 | +62.7% |
| Nov 7, 2022 | After the close | -1.80 | -1.76 | +2.2% |
| Aug 10, 2022 | Before the open | -2.28 | -2.02 | +11.4% |
| May 12, 2022 | After the close | -2.05 | -3.20 |
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021…
| -56.1% |
| Mar 22, 2022 | Before the open | -2.84 | -2.55 | +10.2% |
| Dec 1, 2021 | Before the open | -2.71 | -2.62 | +3.3% |
| Aug 12, 2021 | After the close | 0.00 | -3.92 | — |
| May 11, 2021 | After the close | 0.00 | -3.68 | — |
| Mar 31, 2021 | Time not confirmed | 0.00 | -3.68 | — |